The Latest Breaking News from Pfizer

About half the U.S. state attorneys general have traveled to France for an event cosponsored by a group largely funded by companies

Pfizer has underperformed relative to the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s outlook.

The S&P 500 also closed lower Tuesday, while the Dow Jones Industrial Average managed a win.

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

September S&P 500 E-Mini futures (ESU24) are trending up +0.17% this morning as market participants braced for the start of the Federal Reserve’s two-day policy meeting while also awaiting the latest reading on U.S. job openings as well as an earnings report from tech giant Microsoft.

Pfizer's stock shows signs of a potential rebound, buoyed by recent pipeline successes in hemophilia and obesity treatments, an attractive 5% dividend yield, and a rock-bottom valuation. This makes it an appealing dividend stock for value and income investors as the drug giant prepares to report earnings.

This week we have Apple, Advanced Micro Devices, Amazon, Pfizer, Coinbase, Meta Platforms, Intel, Exxon Mobil, Boeing, PayPal, Starbucks, McDonald’s and Chevron all set to report.

Since May, a number of poultry farms around Australia have faced outbreaks of avian influenza, or bird flu. These outbreaks have been devastating for the poultry farms affected, necessitating large-scale culls, and have caused knock-on effects for the country’s egg supplies.

170 major CEOs unite to denounce political violence after Trump shooting, emphasizing peace and unity.

As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.